Arrowhead Pharmaceuticals (ARWR) Non Operating Income (2010 - 2026)

Arrowhead Pharmaceuticals (ARWR) has 17 years of Non Operating Income data on file, last reported at $3.7 million in Q1 2026.

• Quarterly Non Operating Income rose 131.89% year-over-year to $3.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$30.4 million (up 9.94% YoY) and the FY2025 annual result came in at -$46.8 million, down 311.36% from the prior year.
• Non Operating Income improved to $3.7 million in Q1 2026, from -$12.5 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $3.7 million in Q1 2026 to a low of -$13.7 million in Q4 2024.
• A 5-year average of -$3.7 million and a median of -$680000.0 in 2023 frame the typical range for Non Operating Income.
• The widest YoY moves for Non Operating Income: up 418.24% in 2024, down 1505.3% in 2024.
• Tracing ARWR's Non Operating Income over 5 years: stood at $340000.0 in 2022, then tumbled by 730.59% to -$2.1 million in 2023, then slumped by 539.13% to -$13.7 million in 2024, then grew by 8.5% to -$12.5 million in 2025, then surged by 129.47% to $3.7 million in 2026.
• The last three Non Operating Income figures came in at $3.7 million (Q1 2026), -$12.5 million (Q4 2025), and -$8.0 million (Q3 2025), per Business Quant data.